Company Overview of Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the infectious disease field in the United States. Its product portfolio includes ABT-450, a protease inhibitor that is in Phase III clinical trials for the treatment of hepatitis C virus (HCV); ABT-493, a next-generation protease inhibitor for HCV infection; EDP-239, an NS5A inhibitor for HCV infection; Cyclophilin inhibitor, which are in preclinical development stage for HCV infection treatment; and Nucleotide Polymerase inhibitor program for HCV infection. The company also develops Bicyclolide antibiotic products focuses on mechanisms gram-positive pathogens, including bacteria resistant...
500 Arsenal Street
Watertown, MA 02472
Founded in 1995
Key Executives for Enanta Pharmaceuticals, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $751.8K
Chief Financial Officer and Senior Vice President of Finance & Administration
Total Annual Compensation: $440.3K
Chief Scientific Officer and Senior Vice President of Research & Development
Total Annual Compensation: $514.1K
Compensation as of Fiscal Year 2014.
Enanta Pharmaceuticals, Inc. Key Developments
Enanta Pharmaceuticals, Inc. Announces U.S. Regulatory Approval of TECHNIVIE™ Tablets
Jul 24 15
Enanta Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) approved AbbVie’s TECHNIVIE™ (ombitasvir, paritaprevir and ritonavir) tablets in combination with ribavirin (RBV) for the treatment of non-cirrhotic adults with genotype 4 (GT4) chronic hepatitis C virus (HCV) infection.
Enanta Pharmaceuticals, Inc. Announces the Appointment of Nathalie Adda as Chief Medical Officer
Jun 30 15
Enanta Pharmaceuticals, Inc. announced the appointment of Nathalie Adda, M.D., as Senior Vice President and Chief Medical Officer, responsible for clinical and regulatory affairs. Dr. Adda is a specialist in infectious disease and has more than 15 years of experience in the pharmaceutical industry in all phases of global clinical research and development and commercialization. Most recently, Dr. Adda was Chief Medical Officer, VP Clinical Development, Medical and Regulatory Affairs at Transgene SA, where she led the Oncology and Infectious Disease programs since 2012.
Enanta Pharmaceuticals, Inc. Announces New Data from AbbVie’s Phase 3 Gift-I Study
May 26 15
Enanta Pharmaceuticals, Inc. announced that new data from AbbVie’s phase 3 GIFT-I study, its investigational, all-oral, interferon (IFN)- and ribavirin (RBV)-free, two direct-acting antiviral treatment with ombitasvir/paritaprevir/ritonavir, was presented at the Annual Meeting of the Japan Society of Hepatology in Kumamoto, Japan. GIFT-I evaluated genotype 1b (GT1b) chronic hepatitis C virus (HCV) infected Japanese patients, with and without cirrhosis, who were either treatment-naïve or Interferon (with or without RBV) treatment-experienced. The primary endpoint was achieved, demonstrating 95% (n=106/112) SVR12 in a sub-group of treatment-naïve, non-cirrhotic, adult GT1b HCV infected Japanese patients who were eligible for therapy with IFN and had a high viral load.1 In study results related to the secondary endpoint, GT1b HCV patients with compensated cirrhosis achieved 91% (n=38/42) SVR12. In an additional intent-to-treat (ITT) analysis, SVR12 was achieved in 98% (n=104/106) of the GT1b HCV infected patients without cirrhosis (Arm B) who were randomized to initially receive double-blind placebo for 12 weeks, followed by open-label treatment with ombitasvir/paritaprevir/ritonavir. The ITT population included every patient that was randomized to placebo and received at least one dose of active, open-label study drug. Across all study arms, three patients (n=3/363) discontinued treatment due to adverse events. The most commonly reported adverse events (>5% in any arm) were nasopharyngitis, headache, peripheral edema, nausea, pyrexia and decreased platelet count.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|